EBOS Group - SVS Acquisition—Nice to Have
The acquisition of the final 10% in Transmedic shows promising growth, with a 50% revenue increase from FY22 to FY24, indicating a solid...
483 Views
EBOS Group - 1H25 Result—Upgrade to OUTPERFORM
We upgrade our rating to OUTPERFORM. The result reinforced EBO’s robust operating momentum, and we expect it to reach the top end of its FY25...
185 Views
EBOS Group - 1H25 Preview—Good Delivery
We expect EBOS Group (EBO) to report a 1H25 result slightly ahead of consensus and its outlook commentary to highlight solid operating momentum
257 Views
EBOS Group - Fulfilled the Order—Down to NEUTRAL
We downgrade our rating on EBOS Group (EBO) to NEUTRAL from OUTPERFORM on valuation grounds. The recent Pharmaceutical Wholesaler Agreement (PWA)...
264 Views
EBOS Group - 102nd AGM — Line and Length
EBOS Group's (EBO) 1Q25 trading update was robust, with EBITDA growth of +7.4% excluding the Chemist Warehouse (CW) contract, highlighting it is...
390 Views